Contineum Therapeutics, Inc. (NASDAQ:CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS).RRMS is the most common type of MS, characterized by unpredictable periods of new or worsening symptoms (relapses) followed by periods of recovery (remissions).MS is an autoimmune disease where the immune system attacks the myelin sheath, the protective covering of nerve fibers in the brain and spinal cord.The trial d ...